STOCK TITAN
  1. Home
  2. News
  3. OGN

Organon & Co. - OGN STOCK NEWS

Welcome to our dedicated page for Organon & Co. news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co. stock.

Organon & Co. (OGN) is a science-based global pharmaceutical company dedicated to developing and delivering essential health solutions. Founded in Oss, the Netherlands, Organon originally gained fame for pioneering the birth control pill, which revolutionized women's health. Over the years, the company expanded significantly and was acquired by Schering-Plough, and later by Merck, continuing its legacy as MSD in the Netherlands.

Today, Organon operates with a robust portfolio comprising women's health, biosimilars, and established medicines. The company focuses on providing prescription therapies that address a wide range of health needs, particularly in women's health. Organon's product offerings include innovations in contraception, fertility treatments, and menopause management.

In addition to women's health, Organon is committed to advancing the field of biosimilars - biologically similar products to existing branded drugs that promise to enhance patient access to key treatments. The company's established brands, which include a variety of well-known medications, continue to be a core revenue driver. Geographically, Organon derives most of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions.

Organon remains at the forefront of pharmaceutical innovation, driven by a mission to improve health outcomes globally. The company's strategic partnerships and continued investment in research and development reflect its commitment to addressing some of the most pressing health challenges of our time.

News

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Rhea-AI Summary
Organon (NYSE: OGN) reported a full-year 2023 revenue of $6.3 billion, up 1% as-reported and 3% at constant currency. The company's full-year 2023 diluted earnings per share were $3.99, with non-GAAP adjusted diluted earnings per share at $4.14. Adjusted EBITDA for 2023 was $1.9 billion, with a 31.0% margin. Organon provided full-year 2024 financial guidance with revenue expected in the range of $6.2 billion to $6.5 billion and an Adjusted EBITDA margin of 31.0% to 33.0%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.81%
Tags
earnings
-
News

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

Rhea-AI Summary
Organon, a global healthcare company focusing on women's health, will release its Q4 and full year 2023 financial results on February 15, 2024. The company will host a webcast and conference call at 8:30 a.m. EST. Interested parties can access the live call via webcast and a replay will be available on the company's website. Institutional investors and analysts must register in advance to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
conferences
-
News

Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Rhea-AI Summary
Organon (OGN) introduces XACIATO™ (clindamycin phosphate) vaginal gel 2% to treat bacterial vaginosis, a common condition affecting millions of women. The gel aims to address the physical and emotional impact of BV, disproportionately affecting non-Hispanic Black and Mexican American women. XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.17%
Tags
none
News

Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook

Rhea-AI Summary
Organon (NYSE: OGN) affirms prior revenue and Adjusted EBITDA guidance for full year 2023, expects free cash flow to be above previous range, and provides financial objectives for 2024. The company's annual dividend of $1.12 per share remains its primary capital allocation priority.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.12%
Tags
none
-
News

Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Organon (NYSE: OGN) CEO and CFO to participate in fireside chat at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
conferences
-
News

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Rhea-AI Summary
Organon (NYSE: OGN) becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe, expanding its product portfolio in the central nervous system disorders. The agreement with Eli Lilly and Company (Lilly) involves an upfront payment of $50 million and sales-based milestone payments, with the transaction expected to close in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
none
News

Organon To Present at the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
Organon (OGN) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences
-
News

Organon Reports Results for the Third Quarter Ended September 30, 2023

Rhea-AI Summary
Organon (NYSE: OGN) reported third quarter 2023 revenue of $1,519 million, with diluted earnings per share of $0.23 and non-GAAP adjusted diluted earnings per share of $0.87. The company's adjusted EBITDA was $447 million. The board of directors declared a quarterly dividend of $0.28 per share. Full year 2023 financial guidance ranges were updated, with narrowed and lowered revenue range of $6.15 billion to $6.25 billion and narrowed and lowered adjusted EBITDA margin range of 30.5% to 31.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.51%
Tags
earnings
-
News

Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed

Rhea-AI Summary
Organon and Sempre Health have formed a strategic partnership to improve medication adherence through a pricing program. Eligible patients who refill their prescriptions on time for Dulera and Asmanex will receive discounts on their medications. The program aims to address the high costs and complexity of medication regimens that contribute to non-adherence. Technology integrations and personalized text message engagement will support patients in managing their health and saving money.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
News

Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023

Rhea-AI Summary
Organon to release Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences earnings

FAQ

What is the current stock price of Organon & Co. (OGN)?

The current stock price of Organon & Co. (OGN) is $15.97 as of January 24, 2025.

What is the market cap of Organon & Co. (OGN)?

The market cap of Organon & Co. (OGN) is approximately 4.2B.

What is Organon & Co. known for?

Organon & Co. is known for its contributions to women's health, particularly for pioneering the birth control pill.

What are the main product areas of Organon & Co.?

Organon's main product areas include women's health, biosimilars, and established medicines.

Where does Organon & Co. generate most of its revenue?

Organon generates the majority of its revenue from Europe and Canada, followed by the United States and then Asia Pacific and Japan.

Who previously acquired Organon & Co.?

Organon was previously acquired by Schering-Plough and later by Merck.

What types of products does Organon offer in women's health?

Organon offers products related to contraception, fertility treatments, and menopause management.

What are biosimilars?

Biosimilars are biologically similar products to existing branded drugs, designed to enhance patient access to essential treatments.

How does Organon & Co. contribute to global health?

Organon contributes to global health by developing and delivering essential prescription therapies that address a variety of health needs.

Has Organon & Co. been involved in any recent significant projects or initiatives?

Organon is continuously involved in strategic partnerships and investments in research and development to address pressing health challenges.

What is the history of Organon & Co. in the Netherlands?

Originating in Oss, the Netherlands, Organon is renowned for its historical contributions to women's health, notably the birth control pill, and continued its legacy as MSD after being acquired by Merck.

What is the significance of Organon's established brands?

Organon's established brands are a core revenue driver, comprising a variety of widely used and well-known medications.
Stock OGN logo
Organon & Co.

NYSE:OGN

OGN Rankings

#1423 Ranked by Market Cap
#386 Ranked by Dividends

OGN Stock Data

4.19B
256.95M
0.18%
81.62%
5.93%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
JERSEY CITY